← Back to Search

Behavioral Intervention

VIOME Nutrition Program for Diabetes Prediction

N/A
Waitlist Available
Led By Guruduth Banavar, PhD
Research Sponsored by Viome
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Viome customer
GI test collected at home using Viome test kit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ~3 months
Awards & highlights

Study Summary

This trial is testing whether a model that predicts diabetes and/or risks of developing diabetes is accurate.

Who is the study for?
This trial is for adults over 18 who are living in the US, can speak and read English, and have self-reported type 2 diabetes or prediabetes. Participants must be existing Viome customers who haven't joined other Viome studies, willing to follow instructions, and able to provide a stool sample using the home test kit.Check my eligibility
What is being tested?
The study tests the VIOME Precision Nutrition Program. It collects stool samples from participants and gives them personalized diet and supplement advice. The goal is to develop a model that predicts diabetes risk more accurately.See study design
What are the potential side effects?
Since this trial involves dietary recommendations rather than medication, typical drug side effects aren't expected. However, changes in diet may cause digestive adjustments or food sensitivities.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are a Viome customer.
Select...
You cannot use a Viome test kit to collect a gastrointestinal sample at home.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and ~3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in VIOME's Type 2 diabetes risk score

Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
All participants received the intervention in this trial. They received recommendations on their diets and supplements based on their results of microbiome expression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VIOME Precision Nutrition Program
2020
N/A
~10000

Find a Location

Who is running the clinical trial?

ViomeLead Sponsor
19 Previous Clinical Trials
14,625 Total Patients Enrolled
2 Trials studying Diabetes
152 Patients Enrolled for Diabetes
Guruduth Banavar, PhDPrincipal InvestigatorViome

Media Library

VIOME Precision Nutrition Program (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04905485 — N/A
Diabetes Research Study Groups: Intervention
Diabetes Clinical Trial 2023: VIOME Precision Nutrition Program Highlights & Side Effects. Trial Name: NCT04905485 — N/A
VIOME Precision Nutrition Program (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04905485 — N/A
Diabetes Patient Testimony for trial: Trial Name: NCT04905485 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can any individuals currently participate in the trial?

"As per the clinicaltrials.gov registry, this medical trial is not currently seeking participants. Initial posting was on May 21st 2021 and it has since been updated on June 2nd 2021. Despite its closure, 1624 other trials remain open to new enrollees at this time."

Answered by AI

Who else is applying?

What state do they live in?
Washington
What site did they apply to?
Viome Research Institute
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I want to see if I have a risk of being diabetic as my mother is prediabetic.
PatientReceived no prior treatments
~760 spots leftby Mar 2025